Balanced news tone
News Sentiment
PFE sentiment intelligence
Pfizer Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-0.6% over one week, -7.8% over four weeks, trend inactive, and near fair-value range.
Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Market source
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 11 Jun 2026 07:00
- Source
- 24/7 Wall St.
Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- Market source
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- TradingView
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Apr 2026 07:00
- Source
- The Globe and Mail
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Apr 2026 07:00
- Source
- The Globe and Mail
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- TradingView
If You Invested $1,000 in Pfizer (PFE)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Mar 2026 02:02
- Source
- Stock Titan
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Mar 2026 08:00
- Source
- TradingView
Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Feb 2026 08:00
- Source
- TradingView
With 66% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Nov 2025 08:00
- Source
- Market source
StockWatch: Pfizer’s Deal with Trump Pays off for Investors
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 05 Oct 2025 07:00
- Source
- Genetic Engineering and Biotechnology News
President announces TrumpRx and deal with Pfizer
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Oct 2025 07:00
- Source
- Healthcare Finance News
Why Pfizer’s Trump Deal Is Good News for All of Big Pharma
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Oct 2025 07:00
- Source
- WSJ
US Pfizer deal powers health stocks as drugmakers court Trump
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Oct 2025 07:00
- Source
- Reuters
Trump, Pfizer agree to lower U.S. drug prices, exempt company from pharma tariffs
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 30 Sep 2025 07:00
- Source
- CNBC